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ABSTRACT 
 
Inflammation is often prolonged after sepsis, trauma and other acute pro-inflammatory events, 
particularly above the age of 80 years. Exposure to inflammation of inappropriate amplitude or 
duration is associated with a higher risk of delirium, anorexia, lethargy, low mood, weakness and 
other markers of frailty, and with less favourable clinical outcomes. Theophylline has been shown 
in vitro and in vivo to have an anti-inflammatory effect, probably mediated through induction of 
histone deacetylase-dependent gene switching in immune competent cells. This is mainly 
characterized by a reduction in the production and release of TNFα, IL-1β and IL-6, a consequent 
fall in CRP and increase in IL-10, and a shift of immune cell phenotypes to the anti-inflammatory 
mode. This effect occurs at theophylline concentrations in the 5-10 mg/L range, which is below the 
broncho-dilator range (10-15 mg/L) and carries a relatively low risk of toxicity. We hypothesize that 
low-dose theophylline treatment given to elderly subjects with acute inflammation, for example due 
Mini-review Article 
  
 
 
Allen et al.; BJPR, 14(5): 1-12, 2016; Article no.BJPR.31788 
 
 
 
2 
 
to pneumonia, septicaemia or trauma, will alter the balance of their inflammatory status from an 
inappropriately extended pro-inflammatory pattern toward a more normalized baseline pattern and 
thereby reduce the risk of adverse clinical outcomes. 
 
 
Keywords: Systemic inflammation; old age; frailty; cytokines; theophylline; anti-inflammatory drugs. 
 
1. INTRODUCTION 
 
A substantial body of evidence indicates the 
involvement of systemic inflammation in the 
pathogenesis of several aspects of the frailty 
syndrome [1,2] most frequently encountered in 
old age. This is a complex field that spans clinical 
medicine, immunology, pathology and biological 
chemistry, and there is a fragmentary 
understanding of the regulatory mechanisms 
involved, the range of normative states and the 
variations over time. However, for the purposes 
of this paper the chemical and cellular systemic 
inflammatory status of an individual can be 
broadly envisaged in the following categories:  
 
1. Normal: This is the usual condition of 
healthy individuals between episodes of 
acute inflammation. Various cytokines and 
other bio-chemicals are found in peripheral 
blood in an approximately steady state at 
low concentration, or are undetectable, 
and immune competent cells express a 
mainly surveillance phenotype.  
2.  Chronic low-amplitude inflammation: 
This state is frequently encountered in 
older people, even those who appear to be 
healthy. It is also associated with a wide 
range of chronic pro-inflammatory 
conditions that have a high prevalence in 
elderly people, including chronic 
obstructive pulmonary disease (COPD), 
osteoarthritis, type 2 diabetes, obesity and 
a sedentary lifestyle [3-8]. 
3. Acute inflammation with appropriate 
resolution: This is the normally observed 
response to events such as infection or 
trauma in healthy individuals. Typically, 
there is a rise in circulating pro-
inflammatory bio-chemicals and cells, then 
an anti-inflammatory surge, followed by a 
rapid return to pattern 1 after the initial 
stimulus has been eliminated. 
4. Acute inflammation with inappropriate 
resolution: This is a less well recognized 
but not uncommon response to ostensibly 
ordinary infections, such as pneumonia, 
urinary tract infections, Gram-negative 
septicaemia and cellulitis, or other 
physiological insults such as accidental or 
surgical trauma. In older patients, the pro-
inflammatory phase in such circumstances 
is often prolonged [2,9,10] and is 
associated with a number of clinically 
important consequences such as delirium, 
lethargy, low mood, autonomic 
dysfunction, reduced appetite, weakness 
and increased dependency. There is a 
slow, and sometimes incomplete, return to 
baseline (either pattern 1 or 2). 
Geriatricians and other clinicians involved 
with the care of elderly people are 
becoming increasingly familiar with this 
phenomenon and the adverse effect it can 
have on a range of outcomes for their 
patients.  
5. Overwhelming and dysregulated 
inflammation: This is a comparatively rare 
but torrential and frequently fatal acute 
disorder of innate immunity leading to 
severe sustained systemic inflammation in 
some patients with sepsis, burns or 
trauma, and is usually encountered in the 
critical care setting [11]. It can occur at any 
age but tends to have a very poor 
prognosis in older patients. 
 
As part of this review paper, we will present a 
hypothesis that contends that the outcomes from 
pattern 4, usually encountered in elderly patients 
and sometimes in younger people with chronic 
inflammatory conditions, could be improved by 
using the methyl-xanthine drug theophylline to 
modify the balance of pro-inflammatory and anti-
inflammatory entities (mostly cytokines) closer to 
that observed in pattern 3 so that the deleterious 
effects of extended acute systemic inflammation 
are measurably reduced. 
 
2. BACKGROUND 
 
2.1 Innate Immunity 
 
The cells and cytokines of the innate immune 
system are the first responders to infection and 
other forms of tissue damage. This ancient and 
evolutionarily robust defence mechanism is 
represented in some form in almost all multi-
cellular animals. It operates in advance of and 
modulates adaptive immunity in individual 
organisms and almost certainly evolved much 
earlier [12]. The chemistry and cell biology of 
innate immunity is complex and incompletely 
understood, and it is not the purpose of this 
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paper to attempt an extensive review of that 
topic. However, in support of our hypothesis it is 
necessary to describe some relevant features of 
the system. Though some empirical findings 
have been equivocal or even contradictory there 
is a sufficient amount of consistent research to 
be able to form a useful understanding of a 
number of key processes that are informative 
within the context of this paper. Taking 
pneumococcal infection as an example, in 
individuals with or without adaptive antibody 
immunity, pneumococcal antigens are initially 
presented to tissue macrophages and circulating 
monocytes both directly and as complexes 
bound to C-reactive protein (CRP), serum 
amyloid A (SAA) and toll-like proteins. In 
response, monocytes of pro-inflammatory 
phenotype release pro-inflammatory cytokines of 
the interleukin-1 (IL-1) family, interleukin-6 (IL-6) 
and tumour necrosis factor-α (TNFα), probably 
within 1-3 hours as shown by in vitro studies 
[13,14]. There is some evidence that this process 
is delayed in older patients, based on studies in a 
clinical setting [15], but the pathophysiological 
and clinical significance of that finding is not 
clear. By processes for which there is only a 
partial understanding those cytokines, other less 
extensively studied cytokines, and other bio-
chemicals involved in innate immunity such as 
interferons and complement, stimulate a number 
of responses by a wide range of cell types that 
contribute to an effective elimination of the 
infection. The range of these pro-inflammatory 
effects also includes increased production of 
CRP and SAA by hepatocytes, increased 
endothelial permeability, reduced protein 
synthesis and increased interleukin-6 (IL-6) 
release by various cells including monocytes, 
myocytes and adipocytes, reduced albumin 
synthesis, switching of neutrophils to a pro-
inflammatory phenotype that includes further 
release of pro-inflammatory cytokines including 
TNFα, down-regulation of autonomic 
cardiovascular reflexes, and context-variable 
effects on synthetic functions by other tissues 
and metabolic pathways including glucocorticoid 
and catecholamine production [1,16]. Lethargy 
and an urge to rest, sometimes referred to as 
sickness behaviour, are probably at least partly 
due to cytokine-mediated alterations in central 
nervous system function. There is also 
circumstantial evidence that pro-inflammatory 
cytokines directly predispose to delirium [17], 
though the mechanism is not clear and other 
mechanisms, such as cerebral capillary micro-
coagulation, might be at play. There is a complex 
effect on macrophages leading initially to further 
production of IL-1β, TNFα and the anti-
inflammatory cytokines interleukin-4 (IL-4) and 
IL-1 receptor antagonist (IL-1ra). Antigen-
stimulated monocytes are also self-stimulated to 
release TNF and other cytokines by an autocrine 
mechanism and, through an influence on T-
helper cell function, lead to rapid production and 
release of interferon-γ (IF-γ), which in turn 
contributes to the response to infection by a 
range of interactions with cells of the innate and 
adaptive immune systems [16]. The essential 
concepts of this process are summarized in 
simplified form in Fig. 1. In the early and mature 
phases of this pro-inflammatory response the 
primary purposes of eliminating infection, 
minimising damage and the survival of the 
individual are being served (pattern 3). Once 
infection has been eliminated counter-regulatory 
mechanisms switch the chemokine and cellular 
milieu of the innate immune system to an anti-
inflammatory phase characterized by a rapid fall 
in IL-1β, TNFα, other pro-inflammatory cytokines 
and CRP, a transient rise in blood levels of anti-
inflammatory cytokines such as IL-4, interleukin-
10 (IL-10) and IL-1ra, and a return of immune cell 
phenotypes to mainly anti-inflammatory and 
surveillance mode (pattern 1) [18].  
 
2.2 Innate Immune Responses in Old Age 
 
The control of this process of switching from a 
defensive pro-inflammatory state back to 
baseline is poorly understood and very complex 
but appears to take longer and to be less clearly 
complete in many elderly individuals [9,10,19], 
such that the persistence of an inflamed state 
beyond the time of active infection starts to have 
deleterious effects. Consequently, in many 
elderly people the biochemical and clinical pro-
inflammatory response to acute infection does 
not resolve as quickly as it does in younger 
adults (pattern 4). The rises in IL-1β, TNFα, IL-6 
and CRP persist longer, and the rise in anti-
inflammatory IL-10 is delayed and also prolonged 
[20]. This effect is reflected in the observed time 
course of clinical recovery, and has been 
quantified in research on humans with 
pneumococcal infection and volunteers exposed 
to endotoxin that showed an approximate 2-fold 
longer time for biochemical markers of 
inflammation, such as TNFα and IL-1β, to return 
to baseline in older individuals [9,10]. That 
research was conducted in healthy elderly 
people but evidence indicates that frailer elderly 
patients, with higher levels of background 
inflammation (pattern 2), have an even more 
extended period of persisting inflammation after 
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acute infections [12]. The clinical correlates for 
that phenomenon include persisting anorexia, 
low mood and lethargy, incomplete resolution of 
delirium and CRP levels that do not return fully to 
the normal range. This suggests an impairment 
of regulatory anti-inflammatory function in old 
age that is a likely substrate for slower clinical 
recovery resulting from an extended exposure to 
the clinically negative effects of certain pro-
inflammatory cytokines, particularly TNFα and IL-
1β.  
 
2.3 Chronic Inflammation in Old Age 
 
To set the background further it is important to 
outline the observed inflammatory state 
associated with old age. Baseline biochemical 
markers of inflammation, such as IL-1β, TNFα 
and CRP are often chronically raised 2- to 4- fold 
in the peripheral blood of elderly people (pattern 
2), particularly those above the age of 80 years, 
compared with younger adults [8,21]. The 
reasons for this are not entirely clear, but in 
some individuals, it can be explained by the 
presence of a clinically obvious chronic 
inflammatory pathology such as COPD or 
rheumatoid arthritis [6]. Similar levels of TNFα 
and CRP are often found in elderly people with 
other disorders that are known to have a pro-
inflammatory effect, such as central obesity, 
atherosclerosis or type 2 diabetes [4,22]. Several 
other conditions, common in old age, have been 
shown to be associated with chronically raised 
pro-inflammatory markers, though the cause-
and-effect relationship is less clear. These 
include Alzheimer’s disease, chronic kidney 
disease, osteoarthritis and physical inactivity  
[23-25]. Some studies have described elevated 
baseline CRP and pro-inflammatory cytokines in 
elderly people with no apparent underlying 
chronic disease [8], thus supporting the 
contention that old age is in itself a pro-
inflammatory condition. Of course, an alternative 
interpretation of that observation is that older 
individuals have an appropriate augmentation of 
innate immunity to counteract the neoplastic and 
auto-immune tendencies of the senescent 
phenotype. 
 
In its chronic state, persisting low-amplitude 
inflammation is associated with a number of 
important adverse outcomes, including increased 
all-cause mortality, reduced muscle strength, 
impaired ability to carry out day-to-day essential 
tasks and lower self-reported health status [26]. 
Further, it appears that chronic disease 
progression is at least partly a consequence of 
chronic inflammation and not simply a 
manifestation of it, so there is a complex 
interaction between cause and effect that seems 
to be self-sustaining and deleterious [27]. The 
best example of this is perhaps the endothelial 
inflammation that occurs in atheromatous 
vascular disease, which can be envisaged as a 
destructive endo-vasculitis both resulting from 
and stimulating an enhanced systemic pro-
inflammatory baseline state [28]. This chronic 
slightly inflamed state, with the associated and 
probably consequent increase in vulnerability to 
an overtly frail clinical condition, leads to a 
consideration in the following paragraph of the 
resulting deterioration that occurs when an acute 
infection or trauma is superimposed (Fig. 1). 
 
2.4 Probable Mechanisms for the 
Deleterious Effect of an Extended 
Acute Pro-inflammatory State 
 
It is necessary to consider the possible 
mechanisms whereby TNFα, IL-1β, IL-6 and 
other inflammatory bio-chemicals contribute to 
adverse clinical phenomena. It must be 
emphasized that our description of this is to 
some extent speculative but it is nevertheless the 
starting point for the hypothesis described below. 
To give an important example from the clinical 
perspective we will consider inflammation-
associated neuronal dysfunction. There is 
evidence that pro-inflammatory over-activity and 
inadequate or incomplete anti-inflammatory 
activity contribute to delirium, low mood and 
sickness behaviour all of which are of 
considerable importance in the clinical setting 
[29]. Autonomic dysfunction is another probable 
consequence, though interpretation is to some 
extent confounded by the immuno-regulatory role 
of autonomic neuroendocrine pathways. 
Receptors for several cytokines are present on 
neurons and glial cells, including TNFα, IL-1β, IL-
6 and IL-1ra, and transport systems have been 
demonstrated that enable a number of cytokines 
to enter the cerebro-spinal fluid and brain 
interstitial fluid, including IL-1β, TNFα, IL-6 and 
IL-1ra [30-33]. In animal experiments, it has been 
shown that measurable changes of behaviour, 
such as anorexia, hiding and sleepiness, are 
induced by exposure to IL-1β and TNFα [34], 
which are thought to act via hypothalamic 
neurons. The role of cytokines in neuronal 
function is complex and appears to be both 
deleterious and protective depending on the 
metabolic and patho-physiological context      
[34-36]. Recent in vitro evidence suggests that 
the influence of cytokines on brain function is to a 
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considerable extent mediated by receptors on 
various cell types in the blood-brain barrier, 
leading to changes in permeability and the 
secondary production of pro-inflammatory 
cytokines beyond the barrier by glial cells [35]. In 
any case, the close temporal association of IL-
1β, IL-6 and TNFα elevation in peripheral blood 
with neuronal dysfunction during and after 
infection in old age is strongly suggestive that 
those cytokines are either directly or indirectly 
involved. 
 
Though some of the adverse effects of IL-1β and 
TNFα are due to direct receptor-mediated 
changes in cell metabolism, there is evidence of 
widespread influences of an enhanced pro-
inflammatory state on other metabolic pathways 
and cell functions that are less clearly direct. 
These include changes in insulin sensitivity, 
increased catecholamine and glucocorticoid 
secretion, increased production of reactive 
oxygen species in endothelium, augmented 
production of prostaglandins and stimulation of 
IF-γ release. Important indirect mechanisms 
include complement-mediated micro-coagulation 
as a consequence of a pro-inflammatory state 
[37]. The biological consequences of these 
changes are incompletely understood but some 
of the better described phenomena are of 
considerable importance in clinical geriatric 
practice, particularly the central and peripheral 
neuronal effects described above, reduced 
muscle protein synthesis, impaired myocyte 
function and increased capillary permeability. 
 
2.5 The Anti-inflammatory Properties of 
Theophylline 
 
Theophylline, a methyl-xanthine drug, has been 
used as a phosphodiesterase inhibitor 
bronchodilator for the treatment of asthma and 
COPD for many years. Its efficacy in that clinical 
context is limited by the need to use plasma 
concentrations in a therapeutic range (10-15 
mg/L) that is close to the toxic range (> 20 mg/L) 
and its clinical utility has been diminished by the 
superior performance of beta-2 agonist and anti-
muscarinic bronchodilators. However, it was 
observed that certain favourable patient 
outcomes, such as walking performance, were 
reported in patients with COPD given 
theophylline treatment even when little or no 
measurable change occurred in spirometry 
indices of airways obstruction or arterial blood 
gas tensions, and the effect was also observed 
at low (< 10 mg/L) plasma levels [38]. Further 
research demonstrated anti-inflammatory 
properties of theophylline locally on airways 
inflammation, systemically and in vitro [38,39]. 
Other methyl-xanthine drugs such as 
pentoxifylline have similar properties [40] but the 
body of evidence is greatest for theophylline. 
Though the complete molecular mechanism of 
the anti-inflammatory properties of theophylline 
remains unknown it has been shown that 
theophylline reduces TNFα and IL-1β secretion 
by monocytes and other immune cells and 
increases IL-10 release [41]. This is probably 
mediated through induction of histone 
deacetylase-dependent gene switching toward a 
more anti-inflammatory phenotype in immune 
cells rather than by phosphodiesterase inhibition 
[39,42]. Theophylline also reduces IL-6 levels in 
peripheral blood [43]. IL-6 however, has a 
complex role that is dependent on physiological 
context, such that the sharp transient rise in IL-6 
that occurs after exercise appears to have an 
anti-inflammatory effect, possibly mediated by IL-
10 release but also directly through an up-rating 
of insulin receptor sensitivity and an anti-
sarcopenic influence on skeletal myocytes 
[44,45]. On the other hand, the higher resting 
trough IL-6 levels that are associated with 
chronic and acute pro-inflammatory states and 
trauma appear to increase the risk of delirium 
[17] and are probably pro-sarcopenic [46-49]. 
There is no evidence regarding the effect of 
theophylline or similar drugs on post-exercise IL-
6. The mechanism of these effects appears to be 
due to theophylline-induced re-direction toward 
the anti-inflammatory state via gene switching in 
macrophages and other immune cells which 
have been shown to have several dose-
dependent gene switches that up- and down-
regulate various cytokines [42,50,51]. An 
interesting observation is that subjects with 
COPD treated with the addition of theophylline to 
a standard regimen had lower baseline CRP 
levels and better functional scores compared 
with control subjects [52]. These effects have 
been described as immune “modulation” by 
some authors as it appears that theophylline at 
currently used therapeutic doses tends to reduce 
inflammation without compromising the 
protective effect of an appropriate acute 
inflammatory response to infection, and a recent 
study has shown a reduction in mortality in 
patients with severe sepsis treated with 
theophylline in a critical care setting [53,54]. 
 
Theophylline has been shown to cause a small 
increase in cortisol secretion in normal and 
asthmatic human subjects at doses used for 
broncho-dilatation. This effect was transient and 
tended to revert to baseline after three days, and 
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was offset by increased urinary cortisol excretion, 
and no rise in serum cortisol levels was found 
[55]. Therefore, it is unlikely that these minor 
changes in cortico-steroid dynamics would 
contribute to the anti-inflammatory properties of 
theophylline. 
 
A potentially beneficial anti-inflammatory effect 
also occurs at in vitro theophylline concentrations 
well below the level needed for effective 
broncho-dilatation [56]. At these lower 
concentrations (5-10 mg/L) it is unusual to 
encounter side effects or signs of theophylline 
toxicity, such as tachycardia, cardiac 
arrhythmias, tremor, nausea, diuresis and sleep 
disturbance. Those side effects are largely 
mediated by a combination of adenosine 
receptor blockade and increased release of 
catecholamines in response to theophylline-
stimulated enhancement of intracellular cyclic-
AMP concentration as a consequence of 
phosphodiesterase inhibition. That mechanism is 
a key pathway for broncho-dilatation but is 
probably not the mechanism for the observed 
immune modulation effects. At broncho-dilator 
therapeutic concentration theophylline has been 
shown to increase the basal metabolic rate 
(BMR) significantly in laboratory animals, mainly 
by increasing heart rate, respiratory rate          
and tremor. At lower anti-inflammatory 
concentrations, such an effect on BMR is likely to 
be negligible and of no clinical importance, and 
no measurable effect was found at therapeutic 
concentrations in COPD patients at rest [57]. 
 
2.6 Hypothesis 
 
Based on the evidence presented and cited in 
the paragraphs above we hypothesize that 
theophylline at target plasma levels below 10 
mg/L will down-regulate the pro-inflammatory 
state and reduce the production of TNF and 
other pro-inflammatory components, and 
concomitantly, or consequentially, up-regulate 
the production of IL-10 and other anti-
inflammatory bio-chemicals and immune cell 
phenotypes. We also hypothesize that such an 
alteration in the overall balance of pro-
inflammatory and anti-inflammatory cytokines will 
lead to earlier and more complete resolution of 
the post-infective or post-traumatic systemic 
inflamed state frequently observed in elderly 
patients. In other words, a shift from pattern 4 to 
pattern 3 is predicted (Fig. 2). 
 
We also hypothesize that the predicted 
shortening of the post-infective, or post-
traumatic, inflammatory phase could lead to 
faster recovery from, or even avoidance of, 
important neuronal dysfunctions such as 
delirium, impaired balance, anorexia, low mood, 
lethargy and autonomic impairment, as well as 
reducing generalized oedema, myocyte 
dysfunction, insulin resistance and other adverse 
metabolic states. Thereby, the treated patient is 
expected to have a lower risk of becoming 
overtly cachectic, frail and dependent. In the 
case of infection, it is probable that the stabilizing 
effect on innate immune chemistry that our 
hypothesis predicts will be most beneficial if 
theophylline treatment is started towards the end 
of antibiotic treatment so as to cause no blunting 
of the initial beneficial switch to a protective pro-
inflammatory state as micro-organisms are 
destroyed, but before the detrimental prolonged 
tail of non-resolving inflammation is established. 
The timing for benefit after trauma will probably 
require an earlier introduction of theophylline, 
and for elective surgery it is feasible that a pre-
operative start might be optimal. The ideal 
duration of treatment will probably be in the 3-6 
week range, though further light can only be 
shed on these practical issues by empirical 
research. 
  
2.7 Alternative Immune-modulating Drugs 
 
We acknowledge that drugs in other classes also 
influence the innate inflammatory response. 
Monoclonal antibodies (MCAs) have been used 
with great success in inflammatory diseases, with 
anti-TNF drugs for rheumatoid arthritis being the 
best known example. However, MCAs have the 
disadvantage of being specific for their target 
cytokines or cytokine receptors and therefore 
appear to have a narrower influence on immune 
settings. They also tend to over-suppress some 
aspects of immune surveillance and predispose 
to opportunistic infection and some malignancies, 
particularly lymphomas, though the latter seems 
only to occur after prolonged treatment. They are 
also expensive, have to be given by injection and 
require close monitoring. 
 
Corticosteroids (CSs) have a long track record of 
use as broad-spectrum anti-inflammatory drugs 
that act by down-regulation of pro-inflammatory 
immune cell behaviour rather than by re-
establishing the baseline equilibrium of the innate 
immune system. When used systemically, they 
are limited by their mineralocorticoid effects 
(sodium and water retention), glucocorticoid 
effects (enhanced protein catabolism and 
glucose intolerance), tendency to cause 
increased wakefulness and precipitate delirium, 
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and suppression of cell-mediated immunity. 
Interestingly, there is evidence that the anti-
inflammatory effects of CSs is augmented by 
theophylline, including a steroid-sparing effect 
allowing lower doses and shorter CS courses for 
exacerbations of COPD [58].  
 
 
 
Fig. 1. A simplified schematic representation of TNF and IL-1 release from monocytes in 
response to an antigen and the subsequent effects on various cells, functional changes and 
longer term consequences in individuals with prolonged post-acute inflammation (pattern 4). 
Key: TNF – tumour necrosis factor, IL-1 – interleukin-1, CRP – C-reactive protein, CNS – central nervous system, 
T – probable sites of action of theophylline in its anti-inflammatory role 
 
Fig. 2. Diagram to illustrate the hypothesized influence of theophylline on an aggregated pro-
inflammatory state. It is predicted that treatment with theophylline will shift the curve to the left 
(pattern 4 towards pattern 3) and thereby reduce the patient’s exposure to an inappropriately 
prolonged period of inflammation 
time 
aggregate 
pro-
inflammatory 
state   
normal response     
      (pattern 3) 
prolonged response  
         (pattern 4) 
predicted effect of   
        theophylline 
 baseline state 
(pattern 1 or 2)  
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Thalidomide and related drugs are established 
as anti-inflammatory agents with clinical uses in 
the treatment of leprosy, other mycobacterial 
diseases, and as an adjunctive drug in certain 
oncology chemotherapy regimens. Like methyl-
xanthine drugs, thalidomide appears to have 
subtle immune modulating properties that include 
suppression of pro-inflammatory cell behaviour, 
and a reduction of IL-1β, IL-6 and TNFα release 
[59,60]. It is limited by a wide range of side-
effects at therapeutic doses.   
 
4-aminoquinoline drugs (chloroquine, 
hydroxychloroquine and amodiaquine) have a 
suppressive action on the release if IL-1β, IL-6, 
TNFα and interferon gamma and tend to promote 
an increase in the population of immune cells 
producing IL-10 and IL-4 [61].  They have been 
used as anti-inflammatory drugs in certain auto-
immune disorders such rheumatoid arthritis and 
systemic lupus erythematosus. The effects of low 
doses on cytokine dynamics is not known and at 
usual therapeutic doses a high proportion of 
patients report unpleasant side effects, though 
anti-inflammatory doses are usually lower than 
those used for the treatment of malaria. 
 
Beta-adrenergic receptor blockers, such as 
propranolol and metoprolol, have been found to 
alter innate immune responses, with a tendency 
toward an anti-inflammatory shift. This has 
largely been observed in relation to the 
inflammatory profile seen in chronic heart failure 
and atheromatous vascular disease [62,63]. The 
mechanism is probably by adrenergic receptor 
blockade and a consequent reduction in 
catecholamine-mediated release of pro-
inflammatory cytokines by monocytes.  
 
Statins have an anti-inflammatory effect that 
appears to be independent of, or not directly 
related to, the induced changes in plasma lipids. 
The reduction in endothelial inflammation, 
probably mediated by a protective effect of 
statins on TNF-induced increases in reactive 
oxygen species in endothelial cells, has received 
most attention, but there is evidence of a more 
systemic effect [64]. However, there have been 
no studies of the effect of statins on acute-phase 
inflammation in the context of sepsis and trauma. 
 
3. DISCUSSION AND SUGGESTED 
RESEARCH PATHWAYS TO TEST 
THE HYPOTHESIS 
 
If our hypothesis proves to be correct, it will offer 
opportunities to intervene beneficially to reduce 
the likelihood of progression to overt frailty in 
elderly patients with acute inflammatory 
illnesses, including infection, trauma and elective 
surgery. If low concentrations of theophylline are 
confirmed as being effective it is likely that side 
effect symptoms will be minimal, and the 
treatment therefore acceptable to patients and 
safe. Of course, adjunctive treatment with 
theophylline would not replace other aspects of 
high quality care, such as antibiotics, optimal 
management of co-morbidities, careful fluid and 
electrolyte management and prophylactic anti-
coagulation, all of which can contribute to 
improving clinical and functional outcomes.  
 
It will be necessary to take a somewhat more 
reductive and focussed approach to test the 
hypothesis. Exploration of the mechanisms, 
beginning with identifying the key steps in the 
chain of cause and effect will need to be based 
initially on animal studies, and in the case of 
delirium will probably need to define more 
precisely the effect of theophylline on IL-1, IL-6 
and TNF-induced changes in the function of 
neurons, glial cells and blood-brain barrier 
permeability. There are a number of animal 
models of acute inflammation that can be used to 
quantify the effect of theophylline on cytokine 
responses, behaviour patterns, muscle 
morphology and function.  
 
We argue that it is not essential to try to establish 
a complete understanding of such mechanisms 
before embarking on a clinical intervention trial in 
humans; the full range of mechanisms of action 
of very few drugs have been completely defined, 
and it might not be possible to achieve such a full 
definition in the innate immunity field due to 
immune-regulatory complexity and individual 
variation. However, the body of evidence that 
underpins our hypothesis is sufficiently robust to 
justify a trial of theophylline in humans. The most 
controllable setting is probably elective surgery, 
which obviously allows the pre-traumatic 
inflammatory state to be measured, and 
therefore sets a target baseline identical to either 
pattern 1 or pattern 2 for elderly subjects. A 
controlled model for the effects of sepsis could 
be conducted in volunteers given a standardized 
dose of a bacterial-derived antigen such as 
enterotoxin, which would also facilitate pre- and 
post-exposure measurements to be made. It will 
be important at a later stage to study patients 
with acute infections, perhaps using pneumonia 
or uro-sepsis as the initiating stimuli, because 
these represent a large proportion of cases seen 
in clinical practice. Of course, in such subjects 
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the pre-infection baseline state will not be known. 
In all these empirical frameworks, we envisage     
a randomized placebo-controlled trial of 
theophylline at a target plasma concentration of 
5-10 mg/L with measurements of key plasma 
cytokines (for example IL-1β, TNFα, IL-6, IL-10, 
IL-1ra), other chemokines involved in 
inflammation, serum CRP and albumin, body 
weight, hand-grip, standardized walking 
performance, functional scores (for example 
Barthel Index), psychometric tests (for              
delirium, depression, cognitive impairment), 
length of stay in hospital, discharge care needs, 
30-day all-cause mortality, drug side-effects, 
proportion of trial completers and rate of re-
admission to hospital. Further exploration of the 
concept would depend on the outcomes of such 
initial trials. 
 
4. CONCLUSION 
 
There is a growing understanding of the part 
played by systemic inflammation in the genesis 
of frailty in older people, including the 
progression to sarcopenia. It is also increasingly 
clear that disordered control of the innate 
immune system is a key factor in the 
pathophysiological pathway leading to several 
aspects of the frailty syndrome at all ages, but 
with most of the clinical burden falling on elderly 
patients with chronic inflammatory conditions, or 
delayed resolution of acute inflammation. In such 
patients, in addition to attention to nutrition and 
moderate exercise, there is theoretical, 
laboratory, observational and some clinical 
evidence that a number of drugs with immune 
modulating properties could be used to reduce 
the pro-inflammatory state, with potential benefit 
to wellbeing, physiological performance and 
independent function. Theophylline is arguably 
one of the most attractive candidates for use in 
an anti-inflammatory role because it appears to 
retain its immune-modulating properties at 
plasma concentrations well below the toxic 
range. Properly conducted clinical trials are 
needed to establish the place of theophylline in 
this clinical context. 
 
CONSENT 
 
It is not applicable. 
 
ETHICAL APPROVAL 
 
It is not applicable. 
 
COMPETING INTERESTS 
 
Authors have declared that no competing 
interests exist. 
 
REFERENCES 
 
1. Yeh SS, Schuster MW. Geriatric cachexia: 
The role of cytokines. Am J Clin Nutr. 
1999;70:183-97. 
2. Francheschi C, Campisi J. Chronic 
inflammation (inflammaging) and its 
potential contribution to age-associated 
diseases. J Gerontol A Biol Sci Med Sci. 
2014;69(S1):S4-S9. 
3. Allen SC. Ageing, exercise and the 
chemistry of inflammation. Rev Clin 
Gerontol. 2015;25:73-80. 
4. Casperan CJ, Pereira MA, Curran KM. 
Changes in physical activity patterns in the 
United States, by sex and cross-sectional 
age. Med Sci Sports Exerc. 2000;32:  
1601-9. 
5. Driver JA, Djousse L, Logroscino G, 
Gaziano JM, Kurth T. Incidence of 
cardiovascular disease and cancer in 
advanced age: Prospective cohort study. 
BMJ. 2008;337:a2467. 
6. Chung HY, Cesari M, Anton S, et al. 
Molecular inflammation: Underpinnings of 
aging and age-related diseases. Ageing 
Res Rev. 2009;8:18-30. 
7. Pedersen BK. The anti-inflammatory effect 
of exercise: Its role in diabetes and 
cardiovascular disease control. Essays 
Biochem. 2006;42:105-17. 
8. Bruunsgaard H, Pedersen BK. Age-related 
inflammatory cytokines and disease. 
Immunol Allergy Clin North Am. 2003;23: 
15-39. 
9. Bruunsgaard H, Skinhoj P, Qvist J, 
Pedersen BK. Elderly humans show 
prolonged in vivo inflammatory activity 
during pneumococcal infections. J Infect 
Dis. 1999;180:551-4. 
10. Krabbe KS, Bruunsgaard H, Hansen CM, 
et al. Ageing is associated with a 
prolonged fever response in human 
endotoxemia. Clin  Diagn Lab Immunol. 
2001;8:333-8. 
11. Jaffer U, Wade RG, Gourlay T. Cytokines 
in the systemic inflammatory response 
syndrome. HSR Proc Intensive Care 
Cardiovasc Anesth. 2010;2:161-75. 
12. Hoffman J, Ahira S. Innate immunity. Curr 
Opin Immunol. 2013;25:1-3. 
  
 
 
Allen et al.; BJPR, 14(5): 1-12, 2016; Article no.BJPR.31788 
 
 
 
10 
 
13. DeForge LE, Remick DG. Kinetics of TNF, 
IL-6 and IL-8 gene expression in LPS-
stimulated human whole blood. Biochem 
Biophys Res Comm. 1991;174;18-24. 
14. Jansky L, Reymanova P, Kopecky J. 
Dynamics of cytokine production in human 
peripheral blood mononuclear cells 
stimulated by LPS or infected by Borrelia. 
Physiol Res. 2003;52:593-8. 
15. Shaw AC, Joshi S, Greenwood H, Panda 
A. Aging of the innate immune system. 
Corr Opin Immunol. 2010;22:507-13. 
16. Poon DCH, Ho YS, Chiu K, Chang CC. 
Cytokines: How important are they in 
mediating sickness? Neurosci Biobehav 
Rev. 2013;37:1-10. 
17. Vasunilashorn SM, Ngo L, Inouye SK, et 
al. Cytokines and postoperative delirium in 
older patients undergoing major elective 
surgery. J Gerontol A Biol Sci Med Sci. 
2015;70:1289-95. 
18. Serhan CN, Brain SD, Buckley CD,                   
et al. Resolution of inflammation: State                 
of the art, definitions and terms. J                
Fed Amer Soc Exper Biol. 2007;21:325- 
32. 
19. Castle SD. Clinical relevance of age-
related immune dysfunction. Clin Infect 
Dis. 2000;31:578-85. 
20. Opal SM, Girard TD, Ely WE. The 
immunopathogenesis of sepsis in elderly 
patients. Clin Infect Dis. 2005;41(supp 7): 
S504-S512. 
21. Woods JA, Wilund KR, Martin SA, Kistler 
BM. Exercise, inflammation and aging. 
Aging Dis. 2012;3:130-40. 
22. Cowie CC, Rust KF, Byrd-Holt DD, et al. 
Prevalence of diabetes and impaired 
fasting glucose in adults in the US 
population: NHANES survey 1999-2002. 
Diabetes Care. 2006;29:1263-8. 
23. Kalaria RN, Maestre GE, Arizaga R, et al. 
Alzheimer’s disease and vascular 
dementia in developing countries: 
Prevalence, management and risk factors. 
Lancet Neurol. 2008;7:812-26. 
24. Coresh J, Selvin E, Stevens LA, et al. 
Prevalence of chronic kidney disease in 
the United States. JAMA. 2007;298:2038-
47. 
25. Dagenais S, Garbedian S, Wai EK. 
Systematic review of the prevalence of 
radiographic primary hip osteoarthritis. Clin 
Orthop Relat Res. 2009;467:623-37. 
26. Christian LM, Glaser R, Porter K, Malarkey 
WB, Beversdorf D, Kiecolt-Glaser JK. 
Poorer self-related health is associated 
with elevated inflammatory markers among 
older adults. Psychoneuroendocrinology. 
2011;36:1495-504. 
27. Michaud M, Balardy L, Moulis G, et al. 
Proinflammatory cytokines, aging, and 
age-related diseases. J Amer Med Dir 
Assoc. 2013;14:877-82. 
28. Tousoulis D, Charakida M, Stefanadis C. 
Endothelial function and inflammation in 
coronary artery disease. Heart. 2006;92: 
441-4. 
29. Dantzer R. Cytokine, sickness behaviour, 
and depression. Immunol Allergy Clin 
North Am. 2009;29:247-64. 
30. Banks WA, Kastin AJ, Broadwell RD. 
Passage of cytokines across the blood-
brain barrier. Neuroimmunomodulation. 
1995;2:241-8. 
31. Banks WA. Blood-brain barrier transport of 
cytokines. Neuroimmune Biol. 2008;6:     
93-107. 
32. Yarlagadda A, Alfson E, Clayton AH. The 
blood-brain barrier and the role of 
cytokines in neuropsychiatry. Psychiatry 
(Edgmont). 2009;6:18-22. 
33. Pan W, Stone KP, Hsuchou H, Manda VK, 
Kastin AJ. Cytokine signalling modulates 
blood-brain barrier function. Curr Pharm 
Des. 2011;17:3729-40. 
34. Tizard I. Sickness behaviour, its 
mechanisms and significance. Anim Health 
Res Rev. 2008;9:87-99. 
35. Srinivasan D, Yen JH, Joseph DJ, 
Friedman W. Cell type-specific interleukin-
1 beta signalling in the CNS. J Neurosci. 
2004;24:6482-8. 
36. Carlson NG, Whitney WA, Chen J, Bacchi 
A, Rogers SW, Gahring LC. Inflammatory 
cytokines IL-1 alpha, IL-1 beta, IL-6 and 
TNF alpha impart neuroprotection to an 
excitotoxin through distinct pathways. J 
Immunol. 1999;163:3963-8. 
37. Oikonomopoulou K, Ricklin D, Ward PA, 
Lambris JD. Interactions between 
coagulation and complement: Their role in 
inflammation. Semin Immunopathol 2012; 
34:151-65. 
38. Barnes PJ. Theophylline for COPD. 
Thorax. 2006;61:742-4. 
39. Barnes PJ. Theophylline in COPD. Proc 
Amer Thorac Soc. 2005;2:334-9. 
  
 
 
Allen et al.; BJPR, 14(5): 1-12, 2016; Article no.BJPR.31788 
 
 
 
11 
 
40. Neuner P, Klosner G, Schauer E, et al. 
Pentoxyfylline in vivo down-regulates the 
release of IL-1 beta, IL-6, IL-8 and TNF 
alpha by human peripheral blood 
mononuclear cells. Immunology. 1994;83: 
262-7. 
41. Cvietusa P, Mascali JJ, Negri J, Borish L. 
Anti-inflammatory effects of theophylline: 
Modulation of cytokine production. Ann 
Allergy Asthma Immunol. 1996;77:34-8. 
42. Ito K, Lim S, Caramori G, et al. A 
molecular mechanism of the action of 
theophylline: Induction of histone 
deacetylase activity to decrease 
inflammatory gene expression. Proc Nat 
Acad Sci. 2002;99:8921-6. 
43. Ichiyami T, Hasegawa S, Matsubara T, 
Hayashi T, Furukawa S. Theophylline 
inhibits NF-kappa activation and I kappa B 
alpha degradation in human pulmonary 
epithelial cells. Arch Pharmacol. 2001;364: 
558-61. 
44. Pal M, Febbraio MA, Whitham M. From 
cytokine to myokine: The emerging role of 
IL-6 in metabolic regulation. Immunol Cell 
Biol. 2014;92:331-39. 
45. Pedersen BK, Febbraio M. Muscle-derived 
IL-6: A possible link between skeletal 
muscle, adipose tissue, liver and brain. 
Brain Behav Immun. 2005;19:371-6. 
46. Mikkelsen UR, Couppe C, Karlsen A, et al. 
Life-long endurance exercise in humans: 
Markers and leg muscle size. Mech Ageing 
Dev. 2013;134:531-40. 
47. Woods JA, Veira VJ, Keylock KT. 
Exercise, inflammation and innate 
immunity. Immunol Allergy Rev. 2006;12:  
6-33. 
48. Pedersen BK. Exercise-induced myokines 
and their role in chronic disease. Brain 
Behav Immun. 2011;25:811-6. 
49. Brandt C, Pedersen BK. The role of 
exercise-induced myokines in muscle 
homeostasis and the defence against 
chronic diseases. J Biomed Biotechnol; 
2010.  
Available:http://dx.doi.org/10.1155/2010/52
0258  
(Accessed 3 January 2015). 
50. Spatafora M, Chiappara G, Merendino AM, 
D’Amico D, Bellia V, Bonsignore G. 
Theophylline suppresses the release of 
TNF alpha by blood monocytes and 
alveolar macrophages. Eur Respir J. 1994; 
7:223-8. 
51. Yoshimura T, Usami E, Kurita C, et al. 
Effect of theophylline on the production of 
IL-1 beta, TNF alpha and IL-8 by human 
peripheral blood mononuclear cells. Biol 
Pharm Bull. 1995;18:1405-8. 
52. Subramanian V, Ragulan AB, Jindal A, 
Wiswambhar V. The study of tolerability 
and safety of theophylline given along with 
formoterol plus budesonide in COPD. J 
Clin Diagn Res. 2015;9:10-3. 
53. Hancock REW, Nijnik A, Philpott DJ. 
Modulating immunity as a therapy for 
bacterial infections. Nature Rev Microbiol. 
2012;10:243-54. 
54. Shih YN, Chen YT, Seethala R, Aisiko I, 
Frendl G, Hou P. Effect of the use of 
theophylline and sepsis outcomes. Crit 
Care Med. 2015;43:274. 
55. Tulin-Silver J, Schteingart DE, Mathews 
KP. Effect of theophylline on cortisol 
secretion. J Allergy Clin Immunol 1981;67: 
45-50. 
56. Zhang J, Feng MX, Qu JM. Low dose 
theophylline showed an inhibitory effect on 
the production of IL-6 and IL-8 in primary 
lung fibroblasts from patients with COPD. 
Mediators Inflamm; 2012. 
DOI: 10.1155/2012/492901  
(Accessed June 19 2016) 
57. Mosire K, Renvall MJ, Ramsdell JW, 
Spindler AA. The effect of theophylline on 
metabolic rate in COPD patients. J Am 
Coll Nutr. 1966;15:403-7. 
58. Cosio BG, Iglesias A, Rios A, et al. Low-
dose theophylline enhances the anti-
inflammatory effects of steroids during 
exacerbations of COPD. Thorax. 2009;64: 
424-9. 
59. Bodera P, Stankiewicz W. 
Immunomodulatory properties of 
thalidomide analogs: Pomalidomide and 
lenalidomide, experimental and therapeutic 
applications. Recent Pat Endocr Metab 
Immune Drug Discov. 2011;5:192-6. 
60. Eski M, Sahin I, Sengezer M, Serdar M, 
Ifran A. Thalidomide decreases the plasma 
levels of IL-1 and TNF following burn 
injury: Is it the new drug for modulation of 
systemic inflammatory response. Burns. 
2008;34:104-8. 
61. van den Borne BE, Dijkmans BA, de Rooij 
HH, le Cessie S, Verweij CL. Chloroquine 
and hydroxychloroquine equally affect TNF 
alpha, IL-6 and IF gamma production by 
  
 
 
Allen et al.; BJPR, 14(5): 1-12, 2016; Article no.BJPR.31788 
 
 
 
12 
 
peripheral blood mononuclear cells. J 
Rheumatol. 1997;24:55-60. 
62. Ohtsuka T, Hamada M, Hiasa G, et al. 
Effect of beta-blockers on circulating levels 
of inflammatory and anti-inflammatory 
cytokines in patients with dilated 
cardiomyopathy. J Am Coll Cardiol. 2001; 
37:412-7. 
63. Ulleryd MA, Bernberg E, Yang LJ, 
Bergstrom GML, Johansson ME. 
Metoprolol reduces pro-inflammatory 
cytokines and atherosclerosis in ApoE-/- 
Mice. Biomed Res Internat; 2014. 
DOI: 10.1155/2014/548783  
(Accessed June 10 2016) 
64. Wu K, Tian S, Zhou H, Wu Y. Statins 
protect human endothelial cells from            
TNF-induced inflammation via ERK5 
activation. Biochem Pharmacol. 
2013;85:1753-60. 
 
© 2016 Allen et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
 
  
Peer-review history: 
The peer review history for this paper can be accessed here: 
http://sciencedomain.org/review-history/17912 
